Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/1179545X17695233 http://scihub22266oqcxt.onion/10.1177/1179545X17695233 C5428134!5428134!28579852     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28579852&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28579852.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Clin+Med+Insights+Blood+Disord 2017 ; 10 (ä): ä Nephropedia Template TP {{tp|p=28579852|t=2017. Treatment of Myelofibrosis: Old and New Strategies |pdf=|usr=}}{{28579852}} gab.com Text Treatment of Myelofibrosis: Old and New Strategies JO: Clin Med Insights Blood Disord http://www.kidney.de/pget.php?&tw=1&pmid=28579852 #FOAvip Myelofibrosis (MF) is a BCR-ABL1?negative myeloproliferative neoplasm that is mainly characterised by reactive bone marrow fibrosis, extramedullary haematopoiesis, anaemia, hepatosplenomegaly, constitutional symptoms, leukaemic progression, and shortened survival. As such, this malignancy is still orphan of curative treatments; indeed, the only treatment that has a clearly demonstrated impact on disease progression is allogeneic haematopoietic stem cell transplantation, but only a minority of patients are eligible for such intensive therapy. However, more recently, the discovery of JAK2 mutations has also led to the development of small-molecule JAK1/2 inhibitors, the first of which, ruxolitinib, has been approved for the treatment of MF in the United States and Europe. In this article, we report on old and new therapeutic strategies that proved effective in early preclinical and clinical trials, and subsequently in the daily clinical practice, for patients with MF, particularly concerning the topics of anaemia, splenomegaly, iron overload, and allogeneic stem cell transplantation. Twit Text FOAVip Treatment of Myelofibrosis: Old and New Strategies ????Clin Med Insights Blood Disord http://www.kidney.de/pget.php?&tw=1&pmid=28579852 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28579852 #FOAvip English Wikipedia <ref>{{Cite pmid|28579852}}</ref> Treatment of Myelofibrosis: Old and New Strategies #MMPMID28579852 Iurlo A; Cattaneo D Clin Med Insights Blood Disord 2017[]; 10 (ä): ä PMID28579852show ga Myelofibrosis (MF) is a BCR-ABL1?negative myeloproliferative neoplasm that is mainly characterised by reactive bone marrow fibrosis, extramedullary haematopoiesis, anaemia, hepatosplenomegaly, constitutional symptoms, leukaemic progression, and shortened survival. As such, this malignancy is still orphan of curative treatments; indeed, the only treatment that has a clearly demonstrated impact on disease progression is allogeneic haematopoietic stem cell transplantation, but only a minority of patients are eligible for such intensive therapy. However, more recently, the discovery of JAK2 mutations has also led to the development of small-molecule JAK1/2 inhibitors, the first of which, ruxolitinib, has been approved for the treatment of MF in the United States and Europe. In this article, we report on old and new therapeutic strategies that proved effective in early preclinical and clinical trials, and subsequently in the daily clinical practice, for patients with MF, particularly concerning the topics of anaemia, splenomegaly, iron overload, and allogeneic stem cell transplantation. äTreatment of Myelofibrosis: Old and New Strategies (epmc).pdf DeepDyve Pubget Overpricing